Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-05-07
2004-11-30
Ramsuer, Robert W. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S204000
Reexamination Certificate
active
06825222
ABSTRACT:
BACKGROUND OF THE INVENTION
Peroxisome Proliferator Activated Receptors (PPARs) are members of the nuclear hormone receptor super family, which are ligand-activated transcription factors regulating gene expression. Various subtypes of PPARs have been discovered. These include PPAR&agr;, PPAR&bgr; or NUC 1, PPAR&ggr; and PPAR&dgr;.
The PPAR&agr; receptor subtypes are reported to be activated by medium and long-chain fatty acids. They are involved in stimulating beta-oxidation of fatty acids and with the activity of fibrates which reportedly produce a substantial reduction in plasma triglycerides and moderate reduction in low density lipoprotein (LDL) cholesterol. The PPAR&ggr; receptor subtypes are reportedly involved in activating the program of adipocyte differentiation and are not involved in stimulating peroxisome proliferation in the liver.
Diabetes is a disease in which a mammal's ability to regulate glucose levels in the blood is impaired because the mammal has a reduced ability to convert glucose to glycogen for storage in muscle and liver cells. In Type I diabetes, this reduced ability to store glucose is caused by reduced insulin production. “Type II Diabetes” or “non-insulin dependent diabetes mellitus” (NMDDM) is the form of diabetes which is due to a profound resistance to insulin stimulating or regulatory effect on glucose and lipid metabolism in the main insulin-sensitive tissues, muscle, liver and adipose tissue. This resistance to insulin responsiveness results in insufficient insulin activation of glucose uptake, oxidation and storage in muscle and inadequate insulin repression of lipolysis in adipose tissue and of glucose production and secretion in liver. When these cells become desensitized to insulin, the body tries to compensate by producing abnormally high levels of insulin and hyperinsulemia results. Hyperinsulemia is associated with hypertension and elevated body weight. Since insulin is involved in promoting the cellular uptake of glucose, amino acids and triglycerides from the blood by insulin sensitive cells, insulin insensitivity can result in elevated levels of triglycerides and LDL which are risk factors in cardiovascular diseases. The constellation of symptoms which includes hyperinsulemia combined with hypertension, elevated body weight, elevated triglycerides and elevated LDL is known as Syndrome X.
Current treatment for diabetes mellitus generally first involves treatment with diet and exercise. However, compliance can be poor and as the disease progresses treatment with hypoglycemics, typically sulfonylureas, is often necessary. Sulfonylureas stimulate the &bgr; cells of the liver to secrete more insulin. However, the response of the &bgr; cells eventually fails and treatment with insulin injection is necessary. In addition, both sulfonylurea treatment and insulin injection have the life threatening side effect of hypoglycemic coma. Therefore, patients using these treatments must carefully control dosage.
Thiazolidinediones are a class of compounds which have been shown to increase the sensitivity of insulin sensitive cells. Increasing insulin sensitivity rather than the amount of insulin in the blood reduces the likelihood of hypoglycemic coma. Thiazolidinediones have been shown to increase insulin sensitivity by binding to PPAR&ggr; receptors. However, side effects associated with treatment with thiazolidinediones include weight gain, and, for troglitazone, liver toxicity. PPAR&agr; and PPAR&ggr; receptors have been implicated in diabetes mellitus, cardiovascular disease, obesity, and gastrointestinal disease, such as, inflammatory bowel disease. There exists a need for new pharmaceutical agents which modulate these receptors to prevent, treat and/or alleviate these diseases or conditions while ameliorating side effects of current treatments.
SUMMARY OF THE INVENTION
The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof:
In Structural Formula I, n is 2, 3, or 4. V is O or S. W is O, S, or SO
2
. R
1
is H, a C1-C4 alkyl, phenyl or trifluoromethyl. R
2
are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl. R
3
are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl. R
4
are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl. R
5
are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R
5
is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl. R
6
is H, a C1-C4 alkyl, or an aminoalkyl.
In one embodiment, the present invention relates to a method of modulating a peroxisome proliferator activated receptor by contacting the receptor with at least one compound represented by Structural Formula I, and pharmaceutically acceptable salts, solvates and hydrates thereof
In another embodiment, the present invention also relates to pharmaceutical compositions which include a pharmaceutically acceptable carrier and at least one compound represented by Structural Formula T, and pharmaceutically acceptable salts, solvates and hydrates thereof.
In yet another embodiment, the present invention relates to a method of making a compound represented by Structural Formula I.
The compounds of the present invention and pharmaceutically acceptable salts, solvates and hydrates thereof are believed to be effective in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases because they lower one or more of the following in mammals: glucose, insulin, triglycerides, fatty acids and/or cholesterol. In addition, the compounds exhibit fewer side effects than compounds currently used to treat these conditions.
REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5902726 (1999-05-01), Kliewer et al.
patent: 5994554 (1999-11-01), Kliewer et al.
patent: 0930299 (1999-07-01), None
patent: 2 335 597 (1999-09-01), None
patent: 325250 (1996-12-01), None
patent: 325264 (1996-12-01), None
patent: WO 93/21166 (1993-10-01), None
patent: WO 94/01420 (1994-01-01), None
patent: WO 94/13650 (1994-06-01), None
patent: WO 95/17394 (1995-06-01), None
patent: WO 96/04260 (1996-02-01), None
patent: WO 96/23884 (1996-08-01), None
patent: WO 96/29405 (1996-09-01), None
patent: WO 96/33724 (1996-10-01), None
patent: WO 96/40128 (1996-12-01), None
patent: WO 97/10819 (1997-03-01), None
patent: WO 97/25042 (1997-07-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 97/31907 (1997-09-01), None
patent: WO 97/47612 (1997-12-01), None
patent: WO 98/05331 (1998-02-01), None
patent: WO 98/29120 (1998-07-01), None
patent: WO 98/39006 (1998-09-01), None
patent: WO 98/43081 (1998-10-01), None
patent: WO 98/54220 (1998-12-01), None
patent: WO 98/57631 (1998-12-01), None
patent: WO 99/05161 (1999-02-01), None
patent: WO 99/19313 (1999-04-01), None
patent: WO 99/20275 (1999-04-01), None
patent: WO 99/29317 (1999-06-01), None
patent: WO 99/32465 (1999-07-01), None
patent: WO 99/38850 (1999-08-01), None
patent: WO 99/46232 (1999-09-01), None
patent: WO 99/51740 (1999-10-01), None
patent: WO 99/58510 (1999-11-01), None
patent: WO 99/63983 (1999-12-01), None
patent: WO 00/04889 (2000-02-01), None
patent: WO 00/04890 (2000-02-01), None
patent: WO 00/08002 (2000-02-01), None
Kersten, S., “Roles of PPARs in health and disease,”Nature., 405: 421-424 (2000).
Bright, S.W., “Competitive Particle Concentration Fluorescence Immunoassays for Measuring Anti-diabetic Drug Levels in Mouse Plasma”,Journal of Immunological Methods, 207: 23-31 (1997).
Shinkai, H., “Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl compounds as Hypoglycemic Agents”,J. Med. Chem., 41: 1927-1933 (1998).
Ardecky Robert J.
Brooks Dawn A.
Dominianni Samuel J.
Gossett Lynn S.
Hay David A.
Eli Lilly and Company
Hamilton Brook Smith & Reynolds P.C.
Ramsuer Robert W.
Small Andrea D
LandOfFree
Modulators of peroxisome proliferator activated receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of peroxisome proliferator activated receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of peroxisome proliferator activated receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3311016